ArticleRespiratory research2025
S1PR3 Inhibition in alveolar epithelial cells alleviates pulmonary fibrosis by enhancing alveolar barrier function.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Endothelial S1PR3 downregulation exacerbates pressure overload-induced cardiac remodeling by promoting fibrosis and inflammation.Science China. Life sciences · 2026Article
- Ceramide-Driven Mechanisms in Pulmonary Fibrosis.Metabolites · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPulmonary fibrosis (PF) is a chronic and progressive respiratory disease characterized by the destruction of the alveolar-capillary barrier. Repeated injury and abnormal repair of alveolar epithelial cells lead to barrier dysfunction and fibroblast activation. The sphingosine-1-phosphate (S1P) and sphingosine-1-phosphate receptor (S1PR) signaling pathways are critical for regulating physiological barrier function. Among the five receptor subtypes, S1PR3 is highly expressed in alveolar epithelial cells, especially after injury, but its specific role in PF remains unclear.
methodsPublic single-cell RNA sequencing datasets were analyzed to examine S1PR3 expression in idiopathic pulmonary fibrosis (IPF) patients. The expression pattern of S1PR3 was validated in bleomycin (BLM)-induced PF mice. To explore its functional role, lung epithelial-specific S1pr3 conditional knockout mice were generated. In vitro, S1PR3 expression was knocked down by siRNA or inhibited by the selective antagonist TY52156 to evaluate its effect on epithelial barrier integrity and tight junction proteins.
resultsS1PR3 expression was markedly upregulated in the epithelial cells of both IPF patients and BLM-induced fibrotic mice. Epithelial-specific deletion of S1pr3 significantly attenuated fibrosis, as evidenced by reduced inflammatory cytokine levels, decreased collagen deposition, and improved alveolar-capillary barrier integrity. Furthermore, pharmacological or genetic inhibition of S1PR3 enhanced the expression of tight junction proteins, including ZO-1, Occludin, and Claudin-4, thereby mitigating epithelial barrier disruption.
conclusionsS1PR3 in alveolar epithelial cells plays a critical role in maintaining alveolar-capillary barrier integrity during pulmonary fibrosis. Targeted inhibition of S1PR3 strengthens tight junctions and alleviates inflammation, suggesting that S1PR3 may serve as a promising therapeutic target for PF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.